Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- Wall Street ends down as oil prices, Treasury yields rise
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Oncternal Therapeutics Inc. (ONCT) Increases Previously Announced Bought Deal to $75 Million, Priced at $4.50/sh
December 10, 2020 6:21 AM ESTOncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 16,666,667... More
